ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1532

The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging

sanya Chhikara1, Adinan Kanda2, mohamed Ismail2, Fredrick Ogugua2, Rejowana Rouf2, khaled Ismail2, Parag Bawaskar2, Jerry Molitor2 and Chetan Shenoy2, 1University of Minnesota, New York, NY, 2University of Minnesota, Minneapolis, MN

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Magnetic resonance imaging (MRI), prognostic factors, Scleroderma

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to coronary artery disease, pulmonary, or renal disease. The prevalence of the primary cardiomyopathy of SSc is unknown. Cardiovascular magnetic resonance imaging (CMR) can help accurately determine the presence of, and the cause of cardiomyopathy. We aimed to study the prevalence, the CMR features, and the prognostic implications of the primary cardiomyopathy of SSc.

Methods: We performed a retrospective cohort study of consecutive patients with SSc meeting the 2013 ACR/EULAR classification criteria who had a clinical CMR for suspected cardiac involvement between 2005 and 2020 at our institution. We defined the primary cardiomyopathy of SSc based on a recent systematic literature review and preliminary data-driven, expert consensus-based definition proposed under the auspices of the World Scleroderma Foundation and the Heart Failure Association of the European Society of Cardiology. We investigated the prevalence and the CMR features of the primary cardiomyopathy of SSc, and its association with the long-term incidence of death or major adverse cardiac events (MACE): heart failure hospitalization, ventricular assist device implantation, heart transplantation, and sustained ventricular tachycardia.

Results: Of 130 patients with SSc who had CMR at a median of 3.6 years after diagnosis, 80% were women, the median age was 58 years, 28% had diffuse cutaneous SSc, 34% had pulmonary arterial hypertension, and 54% had interstitial lung disease. On CMR, 22% had an abnormal left ventricular ejection fraction (LVEF), and 40% had late gadolinium enhancement (LGE). Based on abnormal LVEF and/or LGE not attributable to other causes and/or complications, the prevalence of the primary cardiomyopathy of SSc was 21%. A third of these patients had a distinct LGE phenotype which was widespread subendocardial LVLGE in a pattern that always involved the lateral segments, but in some cases, also extended to other segments, without respecting coronary artery territory distributions, and sometimes also involving the right ventricular aspect of the septum, and the right ventricular free wall. Over a median follow-up of 3.6 years after the CMR, patients with the primary cardiomyopathy of SSc had a greater incidence of death or MACE on Kaplan-Meier analyses (log-rank p=0.035). On multivariable Cox proportional hazards regression analyses, the primary cardiomyopathy of SSc was independently associated with greater long-term death or MACE after adjustment for age, pulmonary hypertension, interstitial lung disease, and renal dysfunction (hazard ratio 2.01; 95% confidence interval 1.03-3.92; p=0.041).

Conclusion: Among consecutive patients with SSc meeting the 2013 ACR/EULAR classification criteria who had clinical CMR for suspected cardiac involvement, the prevalence of the primary cardiomyopathy of SSc was 21%. The primary cardiomyopathy of SSc was independently associated with a greater long-term incidence of death or MACE.

Supporting image 1

Prevalence, CMR features, and prognostic implications of the primary cardiomyopathy of SSc. Top – Prevalence of the primary cardiomyopathy of SSc. Middle – CMR features of the primary cardiomyopathy of SSc. Bottom – Prognostic implications of the primary cardiomyopathy of SSc.


Disclosures: s. Chhikara, None; A. Kanda, None; m. Ismail, None; F. Ogugua, None; R. Rouf, None; k. Ismail, None; P. Bawaskar, None; J. Molitor, EICOS Sciences, Aisa Pharma, Inc, Aria CV Inc., Talaris therapeutics; C. Shenoy, None.

To cite this abstract in AMA style:

Chhikara s, Kanda A, Ismail m, Ogugua F, Rouf R, Ismail k, Bawaskar P, Molitor J, Shenoy C. The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-primary-cardiomyopathy-of-systemic-sclerosis-on-cardiovascular-magnetic-resonance-imaging/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-primary-cardiomyopathy-of-systemic-sclerosis-on-cardiovascular-magnetic-resonance-imaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology